The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) guidelines do not currently recommend the use of serum CA 15–3 and CEA for breast cancer screening and directing treatment[14]. Here, CEACAM5 is linked to breast cancer.